A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia

Summary

This is an open-label study to evaluate the safety, tolerability, and efficacy of ABI-2280 in participants with cervical squamous intraepithelial lesions. This study is divided into 2 parts - Part A and Part B. Part A consists of up to 9 dose escalation cohorts. Part B consists of dose expansion cohorts. Participants will self-administer ABI-2280.

Timeline

Start

2022-09-10

Primary completion

2025-10-27

Completion

2025-10-27

Outcome

Outcome not reported

Stopped (Business): “Study terminated early due to Antiva business decision.”

Drugs

Indications